<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Krishna C</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIH HHS</funding><pagination>eadi3808</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11998992</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>383(6685)</volume><pubmed_abstract>Cancer risk is influenced by inherited mutations, DNA replication errors, and environmental factors. However, the influence of genetic variation in immunosurveillance on cancer risk is not well understood. Leveraging population-level data from the UK Biobank and FinnGen, we show that heterozygosity at the &lt;i>human leukocyte antigen (HLA)&lt;/i>-II loci is associated with reduced lung cancer risk in smokers. Fine-mapping implicated amino acid heterozygosity in the &lt;i>HLA&lt;/i>-II peptide binding groove in reduced lung cancer risk, and single-cell analyses showed that smoking drives enrichment of proinflammatory lung macrophages and &lt;i>HLA&lt;/i>-II+ epithelial cells. In lung cancer, widespread loss of &lt;i>HLA&lt;/i>-II heterozygosity (LOH) favored loss of alleles with larger neopeptide repertoires. Thu</pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>An immunogenetic basis for lung cancer risk.</pubmed_title><pmcid>PMC11998992</pmcid><funding_grant_id>DP5 OD028171</funding_grant_id><funding_grant_id>R33 CA263705</funding_grant_id><funding_grant_id>T32 AI078892</funding_grant_id><funding_grant_id>R01 CA283469</funding_grant_id><pubmed_authors>Selvan ME</pubmed_authors><pubmed_authors>Gumus ZH</pubmed_authors><pubmed_authors>Krishna C</pubmed_authors><pubmed_authors>Merad M</pubmed_authors><pubmed_authors>Roudko V</pubmed_authors><pubmed_authors>Lenz TL</pubmed_authors><pubmed_authors>Wilson EA</pubmed_authors><pubmed_authors>Saffern M</pubmed_authors><pubmed_authors>Yoo SK</pubmed_authors><pubmed_authors>Mars N</pubmed_authors><pubmed_authors>Cho BA</pubmed_authors><pubmed_authors>Martinez-Jimenez F</pubmed_authors><pubmed_authors>Chowell D</pubmed_authors><pubmed_authors>Vaninov N</pubmed_authors><pubmed_authors>Tervi A</pubmed_authors><pubmed_authors>Jones SE</pubmed_authors><pubmed_authors>Boffetta P</pubmed_authors><pubmed_authors>Samstein RM</pubmed_authors><pubmed_authors>FinnGen§</pubmed_authors><pubmed_authors>Ollila HM</pubmed_authors></additional><is_claimable>false</is_claimable><name>An immunogenetic basis for lung cancer risk.</name><description>Cancer risk is influenced by inherited mutations, DNA replication errors, and environmental factors. However, the influence of genetic variation in immunosurveillance on cancer risk is not well understood. Leveraging population-level data from the UK Biobank and FinnGen, we show that heterozygosity at the &lt;i>human leukocyte antigen (HLA)&lt;/i>-II loci is associated with reduced lung cancer risk in smokers. Fine-mapping implicated amino acid heterozygosity in the &lt;i>HLA&lt;/i>-II peptide binding groove in reduced lung cancer risk, and single-cell analyses showed that smoking drives enrichment of proinflammatory lung macrophages and &lt;i>HLA&lt;/i>-II+ epithelial cells. In lung cancer, widespread loss of &lt;i>HLA&lt;/i>-II heterozygosity (LOH) favored loss of alleles with larger neopeptide repertoires. Thu</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2025-07-03T03:06:53.797Z</modification><creation>2025-07-03T03:06:53.797Z</creation></dates><accession>S-EPMC11998992</accession><cross_references><pubmed>38386728</pubmed><doi>10.1126/science.adi3808</doi></cross_references></HashMap>